Ms. Roni Kramer, Founder, Chairman and CEO Kamedis Inc.
Roni Kramer founder of Kamedis Dermatology and chairperson of the company for the last 17 years is serving as Kamedis Inc. CEO since October 2015.
An entrepreneur with a strong attraction to Chinese herbs, and an experienced TCM dermatology practitioner with 10 years of experience in treating skin disorders, Roni is leading the Kamedis launch of products in the USA.
Roni attained an M.Sc. in Traditional Chinese Medicine and Chinese herbology at the American College of Traditional Chinese Medicine (ACTCM) in San Francisco, CA, including an internship at Chengdu University and Hospital in Sichuan, China.
Mr. Amichai Bar Nir, CEO.
Mr. Bar-Nir joined Kamedis in August 2015 as CEO.
He has extensive experience in leading companies through the transition from small to large scale business. Prior to joining Kamedis, Mr. Bar-Nir served as the CEO of Pollogen, an innovative company in development, marketing and sales of invasive and non-invasive aesthetic medical devices and Skin care products. Previously, Mr. Bar-Nir was CEO of CogniFit, a software company that specializes in programs that assess and train cognitive abilities and B-Plan, a company that develops business planning tools. He has extensive international sales and marketing experience as well as a technical and operational background Mr. Bar-Nir earned his BA, Economics and Business Administration from the University of Haifa.
Dr. Yonit Bomstein, Ph.D., MBA, CTO and Head of R&D
Dr. Yonit Bomstein joined Kamedis in 2010, bringing extensive practical and managerial experience in the biopharmaceutical industry, clinical research, biotechnological and pharmaceutical discovery and development, business development, and operational strategic management.
Dr. Bomstein served as CEO at a clinical-stage biotech company developing an immunomodulating treatment for Premenstrual Syndrome. She previously held a position as VP R&D leading a preclinical program for an anti-melanoma immunotherapeutic drug at a biotechnology company GammaCan. Prior thereto Dr. Bomstein led a preclinical project supporting clinical trials under FDA at a biopharmaceutical company Proneuron Biotechnologies that is being developed autologous immune cell therapy for severe spinal-cord injuries.
Dr. Bomstein holds a Ph.D. in Immunology from the Weizmann Institute of Science, and an MBA from Tel-Aviv University.
Dr. Deganit Barak-Shinar, Ph.D., VP Clinical, Regulation and QA
Leading the clinical and regulatory activities at Kamedis, Dr. Deganit Barak-Shinar manages clinical research and trials, regulation, FDA and CE submissions, and collaboration with physicians and clinicians worldwide.
With over 10 years of experience in the bio-medical industry, Dr. Barak-Shinar held, prior to Kamedis, executive positions at several bio-medical companies in the fields of cardiology, sleep medicine and gynecology. Her broad experience includes also business development, strategic marketing, and clinical- research and trials.
She holds a Ph.D. in Bio-Medical Engineering from Tel-Aviv University, and her research and published papers focused on advanced models of non-invasive medical sensors. She holds an M.Sc. from Tel Aviv University and a B.Sc. from the Technion - Israel Institute of Technology (both Magna Cum Laude).